HORGEN, Switzerland, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”) announced today the start of a Phase 1 clinical trial evaluating NM32, a next generation tri-specific ...
This is an undesirable program. This file has been identified as a program that is undesirable to have running on your computer. This consists of programs that are misleading, harmful, or undesirable.
NM32 is a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignancies Low molecular weight of NM32 ...
NM32 is a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignancies Low molecular weight of NM32 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results